Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galapagos NV (NASDAQ:GLPG)

81.34
Delayed Data
As of 12:14pm ET
 -0.76 / -0.93%
Today’s Change
40.86
Today|||52-Week Range
82.67
+26.72%
Year-to-Date
Galapagos Begins Cystis Fibrosis Treatment Study
Mar 22 / GuruFocus News - Paid Partner Content
Can The Uptrend Continue for Galapagos (GLPG)?
Mar 16 / Zacks.com - Paid Partner Content
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos ...
Mar 20 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close82.10
Today’s open81.45
Day’s range80.88 - 81.47
Volume35,885
Average volume (3 months)86,916
Market cap$3.8B
Dividend yield--
Data as of 12:14pm ET, 03/23/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)--
Earnings growth (next 5 years)-77.90%
Revenue growth (last year)+227.41%
P/E ratio--
Price/Sales21.24
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PTHNPatheon NV-0.01-0.04%
VRXValeant Pharmaceutic...+0.21+1.96%
MDCOMedicines Co+0.55+1.11%
CTLTCatalent Inc+0.15+0.53%
Data as of 12:31pm ET, 03/23/2017

Financials

Next reporting dateApril 28, 2017
EPS forecast (this quarter)-$0.63
Annual revenue (last year)$143.0M
Annual profit (last year)$59.6M
Net profit margin41.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Executive Director
Onno van de Stolpe
Chief Financial Officer
Bart Filius
Corporate headquarters
Mechelen, Brussels Region

Forecasts


Search for Jobs